...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
【24h】

Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.

机译:分次放疗期间烟酰胺与多潘立酮合用的药理作用和毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Treatment of head and neck tumors by the ARCON regimen has yielded high local control rates. As a result of this treatment intensification there was some increase in mainly acute toxicity of radiotherapy, but nicotinamide by itself has specific side effects such as nausea and vomiting. Due to these side effects and with the initial dose of 80 mg/kg, 31% of the patients discontinued nicotinamide intake. The aim of the study was to investigate the effect of a dose reduction to 60 mg/kg, and the addition of domperidone on the side effects of nicotinamide and its pharmacokinetic profile. PATIENTS AND METHODS: In 22 patients blood plasma nicotinamide levels were determined after intake of 60 mg/kg nicotinamide. A next group of 87 patients received 60 mg/kg nicotinamide in combination with domperidone. In ten of these patients blood plasma nicotinamide levels were also determined. A full pharmacokinetic profile was constructed over the first 24 h after intake of the first drug dose. Furthermore, daily plasma levels at 1 h after nicotinamide intake was determined in the first and last weeks of radiotherapy. All patients were treated according to the ARCON schedule. RESULTS AND DISCUSSION: The mean maximum plasma nicotinamide concentration was 793 nmol/ml without domperidone and 776 nmol/ml with domperidone. The median time at which the maximum concentration occurred was not significantly different for 60 mg/kg nicotinamide without or with domperidone (0.46 versus 0.54 h). The side effects were drastically reduced if nicotinamide was accompanied by domperidone. The percentage of patients that stopped nicotinamide intake was reduced from 32% without domperidone to 14% with domperidone. No correlation was found between the plasma peak concentrations of nicotinamide and the severity of side effects. CONCLUSION: The currently used dose of 60 mg/kg nicotinamide results in a 30% reduction in peak plasma concentrations compared with 80 mg/kg nicotinamide. If nicotinamide was given in combination with domperidone, 86% of the patients continued the nicotinamide medication until the end of the treatment period.
机译:背景与目的:ARCON方案治疗头颈部肿瘤已获得很高的局部控制率。由于这种治疗的加强,放疗的主要急性毒性有所增加,但是烟酰胺本身具有特殊的副作用,例如恶心和呕吐。由于这些副作用,初始剂量为80 mg / kg,因此31%的患者停止了烟酰胺摄入。该研究的目的是研究降低剂量至60 mg / kg的作用以及添加多潘立酮对烟酰胺的副作用及其药代动力学的影响。患者和方法:在22例患者中,摄入60 mg / kg烟酰胺后测定血浆烟酰胺水平。下一小组的87名患者接受了60 mg / kg烟酰胺和多潘立酮的联合治疗。在其中十名患者中,还测定了血浆烟酰胺水平。在摄入第一个药物剂量后的最初24小时内,完整的药代动力学特征被建立。此外,在放疗的最初和最后几周测定了摄入烟酰胺后1小时的每日血浆水平。所有患者均按照ARCON时间表接受治疗。结果与讨论:最高平均烟酰胺浓度为无多潘立酮时为793 nmol / ml,有多潘立酮时为776 nmol / ml。对于有或没有多潘立酮的60 mg / kg烟酰胺,最大浓度出现的中位时间无显着差异(0.46 vs 0.54 h)。如果烟酰胺与多潘立酮联合使用,副作用将大大降低。停止烟酰胺摄入的患者百分比从无多潘立酮的32%降低为有多潘立酮的14%。在烟酰胺的血浆峰值浓度和副作用的严重程度之间未发现相关性。结论:与80 mg / kg烟酰胺相比,当前使用的60 mg / kg烟酰胺剂量可使峰值血浆浓度降低30%。如果将烟酰胺与多潘立酮联用,则86%的患者会继续使用烟酰胺药物,直到治疗期结束。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号